Business Context and Reporting Period
Company: PRO DEX INC (Pro-Dex)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended June 30, 2011
Business Overview: Pro-Dex designs, develops, and manufactures powered surgical devices, fractional horsepower motors, and motion control software/hardware for medical, aerospace, military, and industrial applications. Operations are located in Irvine, California; Carson City, Nevada; and Beaverton, Oregon.
Key Financial Metrics
| Metric | Fiscal 2011 | Fiscal 2010 |
|---|---|---|
| Net Sales | $27,109,000 | $23,211,000 |
| Gross Profit | $10,536,000 (39% margin) | $8,364,000 (36% margin) |
| Net Income (Loss) | $2,640,000 | ($2,968,000) |
| EPS (Basic/Diluted) | $0.81 / $0.80 | ($0.92) / ($0.92) |
| Cash and Cash Equivalents | $4,689,000 | $3,794,000 |
| Working Capital | $7,819,000 | $6,369,000 |
| Backlog | $14.3 million | $11.2 million |
| Debt (Bank Term Loan) | $1,131,000 outstanding | $1,367,000 outstanding (Wells Fargo) |
Note: Fiscal 2010 included non-recurring impairment charges totaling $4,444,000 related to goodwill, patents, and property value.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 17% ($3.9 million) driven primarily by a 23% increase in medical device sales, largely due to volume growth from the largest customer.
- Profitability Turnaround: The company moved from a net loss of $2.97 million in 2010 to a net income of $2.64 million in 2011. This was aided by the absence of the $4.44 million impairment charges recorded in 2010 and improved gross margins.
- Debt Restructuring: In February 2011, the company refinanced its Wells Fargo credit facility with a new agreement with Union Bank, including a $1.25 million term loan. The company also fully retired a $1.52 million mortgage on its Carson City property in September 2010.
- Customer Concentration: The top 20 customers accounted for 89% of sales in 2011 (up from 88% in 2010). The single largest customer accounted for 45% of total sales.
Outlook, Risks, and Contingencies
- Major Customer Risk: The company's largest customer (45% of sales) notified Pro-Dex in June 2011 that it plans to manufacture its own surgical devices, replacing Pro-Dex products. The customer intends to fulfill existing orders (approx. $5 million) but will not place new orders. Revenue from this customer is expected to decline in FY2012 and could drop to zero by the end of FY2012.
- Strategic Response: Management is implementing a strategic plan to identify new revenue opportunities and is prepared to reduce operating costs to mitigate the impact of potential revenue loss.
- Legal Settlement: In April 2011, the company settled a groundwater contamination lawsuit with the Orange County Water District for $250,000. The amount was paid by the company's insurer, resulting in no material adverse impact on cash flow.
- Regulatory Risks: Operations are subject to FDA and EPA regulations. The company faces potential impacts from the Patient Protection and Affordable Care Act, including a 2.3% medical device excise tax effective January 1, 2013.
- Liquidity: Management believes cash on hand, operating cash flows, and available credit facilities ($1.5 million revolving line) are sufficient to meet requirements for fiscal year 2012.
Investor Verification Checklist
- Customer Diversification: Verify the progress of the strategic plan to replace revenue from the largest customer, which is expected to cease new orders.
- Backlog Quality: Assess the composition of the $14.3 million backlog to determine how much is attributable to the departing customer versus new or stable accounts.
- Cost Reduction Execution: Monitor the company's ability to reduce operating expenses in line with projected revenue declines to maintain profitability.
- Debt Covenants: Review compliance with the new Union Bank credit facility covenants, specifically minimum quarterly liquidity and annual profitability thresholds.
- Regulatory Compliance: Confirm ongoing compliance with FDA regulations and the potential financial impact of the upcoming medical device excise tax.